Literature DB >> 2955117

An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa.

F Lanza, M F Rack, M Lynn, J Wolf, M Sanda.   

Abstract

To assess the effects of various nonsteroidal antiinflammatory drugs on gastroduodenal mucosa, 72 normal men were administered either etodolac, indomethacin, ibuprofen, naproxen, or placebo for 7 days. Gastric and duodenal mucosa were scored before and after treatment by direct endoscopy and evaluation of photographs taken during endoscopy. Subjects treated with indomethacin, ibuprofen, and naproxen had significantly worse direct gastric scores, and those treated with indomethacin and naproxen also had significantly worse direct duodenal scores, when compared with pre-treatment and placebo scores. Subjects given either of 2 doses of etodolac had gastric and duodenal scores comparable to pretreatment and placebo scores. The direct gastric scores of the etodolac groups were significantly better than the scores of subjects receiving indomethacin, ibuprofen and naproxen. Similar results were obtained when endoscopy photographs were scored.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2955117

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  20 in total

Review 1.  Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs.

Authors:  J Y Jouzeau; B Terlain; A Abid; E Nédélec; P Netter
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

2.  A randomized, double-blind, one-week study comparing effects of a novel COX-2 inhibitor and naproxen on the gastric mucosa.

Authors:  James B Moberly; Stuart I Harris; Dennis S Riff; James Craig Dale; Tara Breese; Patrick McLaughlin; Janet Lawson; Yaping Wan; Jianbo Xu; Kenneth E Truitt
Journal:  Dig Dis Sci       Date:  2007-01-10       Impact factor: 3.199

Review 3.  Differences in NSAID tolerability profiles. Fact or fiction?

Authors:  K J Skeith; M Wright; P Davis
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

Review 4.  Naproxen. A reappraisal of its pharmacology, and therapeutic use in rheumatic diseases and pain states.

Authors:  P A Todd; S P Clissold
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

5.  Indomethacin and pancreatic enzymes synergistically damage intestine of rats.

Authors:  R E Kimura; V Arango; J Lloyd-Still
Journal:  Dig Dis Sci       Date:  1998-10       Impact factor: 3.199

Review 6.  Ibuprofen: pharmacology, efficacy and safety.

Authors:  K D Rainsford
Journal:  Inflammopharmacology       Date:  2009-11-21       Impact factor: 4.473

7.  A comparison of the efficacy of etodolac SR (Lodine SR) and etodolac (Lodine) in patients with rheumatoid arthritis or osteoarthritis.

Authors:  R L Dreiser
Journal:  Rheumatol Int       Date:  1993       Impact factor: 2.631

8.  Meta-analysis of two double-blind comparative studies with the sustained-release form of etodolac in rheumatoid arthritis.

Authors:  F Porzio
Journal:  Rheumatol Int       Date:  1993       Impact factor: 2.631

9.  The safety profile of sustained-release etodolac.

Authors:  M Schattenkirchner
Journal:  Rheumatol Int       Date:  1993       Impact factor: 2.631

10.  Worldwide experience with etodolac (Lodine) 300 mg b.i.d. in the treatment of osteoarthritis.

Authors:  P Bacon
Journal:  Rheumatol Int       Date:  1993       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.